5,6-Diamino-1,3-dimethyluracil hydrate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5,6-Diamino-1,3-dimethyluracil hydrate
• 英文别名: 5,6-diamino-1,3-dimethyluracil monohydrate；1,3-dimethyl-5,6-diaminouracil hydrate；5,6-diamino-1,3-dimethylpyrimidine-2,4-dione;hydrate
• 化学式: C₆H₁₀N₄O₂*H₂O
• 分子量: 188.186
• InChiKey: FNLDCZCNGSQKIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.58
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  93.7
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5,6-Diamino-1,3-dimethyluracil hydrate 在 氨 作用下， 以 乙醇 为溶剂， 反应 49.0h， 生成 1,3-dimethyl-8-β-D-ribofuranosylxanthine
  参考文献：
  名称：

  2-β-d-ribofuranosylbenzoxazole from 2,5-anhydro-d-allonoimidate, and 1,3-dimethyl-8-β-d-ribofuranosylxanthine from 2,5-anhydro-d-allono-thioimidates and -dithioates

  摘要：

  DOI：

  10.1016/s0008-6215(00)90269-6

文献信息

• [EN] PURINE DERIVATIVES AS LIVER X RECEPTOR AGONISTS<br/>[FR] AGONISTES DES RECEPTEURS X DU FOIE
  申请人：GLAXO GROUP LTD

  公开号：WO2004009091A1

  公开（公告）日：2004-01-29

  The invention relates to methods for the treatment or prevention of an LXR mediated disease or condition, including cariovascular disease and atherosclerosis, novel compounds for use in such methods and pharmaceutical compositions comprising compounds for use in such methods.

  本发明涉及用于治疗或预防LXR介导的疾病或状况的方法，包括心血管疾病和动脉粥样硬化，以及用于此类方法的创新化合物和包含用于此类方法的化合物的药物组合物。
• [EN] BIFUNCTIONAL ALPHA-SYNUCLEIN BINDING AGENTS AND USES THEREOF<br/>[FR] AGENTS DE LIAISON ALPHA-SYNUCLÉINE ET LEURS UTILISATIONS
  申请人：UNIV SASKATCHEWAN

  公开号：WO2018045464A1

  公开（公告）日：2018-03-15

  Bifunctional molecules having first and second alpha-synuclein binding agents coupled by a linker are disclosed. The bifunctional molecules have potential utility in the diagnosis, treatment and/or prophylaxis of disorders in which alpha-synuclein is implicated, including Parkinson's disease. Methods of making and using the bifunctional molecules are disclosed.

  公开了具有第一和第二α-突触核蛋白结合剂通过连接器偶联的双功能分子。这些双功能分子在诊断、治疗和/或预防α-突触核蛋白涉及的疾病方面具有潜在的应用价值，包括帕金森病。还公开了制造和使用这些双功能分子的方法。
• Genetically engineered enzymes and their conjugates for diagnostic assays
  申请人：Abbott Laboratories

  公开号：US05843634A1

  公开（公告）日：1998-12-01

  This invention relates to genetically engineered enzymes, their ligand conjugates, their manufacture, and their use in qualitative or quantitative assays. A hybrid enzyme, such as an AP-epitope, has a foreign amino acid moiety (an epitope) inserted near the active site of the starting AP enzyme. The foreign amino acid moiety binds with an analyte, and, as a consequence of this binding, the enzymatic activity of the hybrid enzyme, AP-epitope, is modified. The changes in the enzymatic activity are dependent upon the presence, or the amount, of the analyte. In another embodiment, the hybrid enzyme consists of a cysteine introduced near the active site of an AP to give a hybrid enzyme. The cysteine on the hybrid enzyme serves as a point of conjugation of a ligand, such as theophylline, ferritin, thyroxine, or digoxigenin, to form the hybrid enzyme-ligand conjugate. The ligand binds with an antibody, an analyte or a binding molecule to an analyte and as a result of this binding, the enzymatic activity of the hybrid enzyme-ligand conjugate is modified or modulated.

  这项发明涉及基因工程酶、它们的配体缀合物、它们的制造方法以及它们在定性或定量分析中的应用。一种杂交酶，如AP-表位酶，在起始AP酶的活性位点附近插入了一个外源氨基酸残基（一个表位）。外源氨基酸残基与一个分析物结合，由于这种结合，杂交酶AP-表位的酶活性被改变。酶活性的变化取决于分析物的存在或数量。在另一实施例中，杂交酶由在AP的活性位点附近引入的一个半胱氨酸形成。杂交酶上的半胱氨酸作为配体（如茶碱、铁蛋白、甲状腺素或地高辛）缀合的位点，以形成杂交酶-配体缀合物。配体与抗体、分析物或与分析物结合的分子结合，由于这种结合，杂交酶-配体缀合物的酶活性被改变或调节。
• Substituted imidazo-fused 6-membered heterocycles as angiotensin II
  申请人：Merck & Co., Inc.

  公开号：US05332744A1

  公开（公告）日：1994-07-26

  Substituted Imidazo-fused 6-membered heterocycles of structural formula: ##STR1## wherein A, B, C, and D are independently carbon atoms or nitrogen atoms are angiotensin II antagonists useful in the treatment of hypertension and congestive heart failure.

  结构式为：##STR1## 其中A、B、C和D分别是碳原子或氮原子的咪唑融合的6元杂环，是用于治疗高血压和充血性心力衰竭的血管紧张素II拮抗剂。
• Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives
  申请人：The United States of America as represented by the Department of Health

  公开号：US04612315A1

  公开（公告）日：1986-09-16

  Certain functionalized congeners of 1,3-dialkylxanthine exhibit high potency and selectivity as antagonists for A.sub.1 - and A.sub.2 -adenosine receptors and are suitable for attachment to probes, drug carriers, or solid supports. These derivatives are characterized by the presence of a phenyl at the 8 position para-substituted with a functionalized chain to provide high water solubility and high receptor affinity to such an extent that these compounds are suitable for use as antiallergenic, antiasthmatic, or cardiotonic drugs, central nervous system stimulants, and diuretics.

  某些功能化的1,3-二烷基黄嘌呤衍生物作为A.sub.1-和A.sub.2-腺苷受体的拮抗剂表现出高效性和选择性，并适合连接到探针、药物载体或固体支持物上。这些衍生物的特点是在8位置带有苯基，对位取代为功能化链以提供高水溶性和高受体亲和力，使得这些化合物适合用作抗过敏、抗哮喘或强心药、中枢神经系统兴奋剂和利尿剂。